At a glance
ClinicalIndex Comparison RecordN/ACompleted· 109 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, As Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders
In Brief
An observational study for Chronic Lymphocytic Leukaemia. Completed, enrolled 109 participants across 3 sites.
Detailed Summary
The purpose of this study is collect and evaluate the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukaemia
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
Primary CompletionDec 2010
Study CompletionJan 2011
First PostedApr 2013
TodayJul 2026
First PostedApr 16, 2013
Enrollment StartNov 1, 2010
Primary CompletionDec 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.2 years ago